Nana Petroula, Kouvelos George, Brotis Alexandros, Spanos Konstantinos, Dardiotis Efthimios, Matsagkas Miltiadis, Giannoukas Athanasios
Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41334 Larissa, Greece.
Department of Neurosurgery, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, 38221 Volos, Greece.
J Clin Med. 2021 Mar 1;10(5):935. doi: 10.3390/jcm10050935.
Most data in carotid stenosis treatment arise from randomized control trials (RCTs) and cohort studies. The aim of this meta-analysis was to compare 30-day outcomes in real-world practice from centers providing both modalities.
A data search of the English literature was conducted, using PubMed, EMBASE and CENTRAL databases, until December 2019, using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement (PRISMA) guidelines. Only studies reporting on 30-day outcomes from centers, where both techniques were performed, were eligible for this analysis.
In total, 15 articles were included (16,043 patients). Of the patients, 68.1% were asymptomatic. Carotid artery stenting (CAS) did not differ from carotid endarterectomy (CEA) in terms of stroke (odds ratio (OR) 0.98; 0.77-1.25; = 0%), myocardial ischemic events (OR 1.03; 0.72-1.48; = 0%) and all events (OR 1.0; 0.82-1.21; = 0%). Pooled stroke incidence in asymptomatic patients was 1% (95% CI: 0-2%) for CEA and 1% for CAS (95% CI: 0-2%). Pooled stroke rate in symptomatic patients was 3% (95% CI: 1-4%) for CEA and 3% (95% CI: 1-4%) for CAS. The two techniques did not differ in either outcome both in asymptomatic and symptomatic patients.
Carotid revascularization, performed in centers providing both CAS and CEA, is safe and effective. Both techniques did not differ in terms of post-procedural neurological and cardiac events, both in asymptomatic and symptomatic patients. These findings reiterate the importance of a tailored therapeutic strategy and that "real-world" outcomes may only be valid from centers providing both treatments.
颈动脉狭窄治疗的大多数数据来自随机对照试验(RCT)和队列研究。本荟萃分析的目的是比较提供这两种治疗方式的中心在实际临床中的30天预后情况。
按照系统评价和荟萃分析的首选报告项目(PRISMA)指南,使用PubMed、EMBASE和CENTRAL数据库对英文文献进行数据检索,直至2019年12月。只有报告了同时开展这两种技术的中心30天预后情况的研究才符合本分析的要求。
共纳入15篇文章(16043例患者)。其中,68.1%的患者无症状。在卒中方面(优势比(OR)0.98;0.77 - 1.25;P = 0%)、心肌缺血事件方面(OR 1.03;0.72 - 1.48;P = 0%)以及所有事件方面(OR 1.0;0.82 - 1.21;P = 0%),颈动脉支架置入术(CAS)与颈动脉内膜切除术(CEA)无差异。无症状患者中,CEA的合并卒中发生率为1%(95%CI:0 - 2%),CAS为1%(95%CI:0 - 2%)。有症状患者中,CEA的合并卒中率为3%(95%CI:1 - 4%),CAS为3%(95%CI:1 - 4%)。在无症状和有症状患者中,这两种技术在任何一种预后方面均无差异。
在同时提供CAS和CEA的中心进行颈动脉血运重建是安全有效的。在无症状和有症状患者中,这两种技术在术后神经和心脏事件方面均无差异。这些发现再次强调了个体化治疗策略的重要性,以及“实际临床”预后可能仅在提供这两种治疗的中心才有效。